DizzyDean wrote:Actually I wouldn't be so cynical. I think that this is a fairly significant data point showing copaxone really does slow the disease down even over the long haul. The reduction in relapses to 0.1 (1 per 10 years) has a VERY impressive level of significance (p < 0.0001). Copaxone really struggled with measures of statistical significance in their original FDA approval studies.
I can't help but wonder - "how did you get 22 years of data on a drug that's only been FDA approved for 11?". Many in the medical community have always been a bit skeptical of copaxone's lengthy time to approval. Has to do with those p-values...
Another question...how did this study control for survivor bias...e.g. only those for whom the medicine worked well (and was tolerable) would stay on it for a long period of time. Hence the study tends to not include those who migrated to other treatments.
I confess I like seeing studies like this 'cause I take the stuff and want it to work well for me!
Users browsing this forum: No registered users